Document Detail

Racial disparities in tissue plasminogen activator treatment rate for stroke: a population-based study.
MedLine Citation:
PMID:  21719765     Owner:  NLM     Status:  MEDLINE    
BACKGROUND AND PURPOSE: Some prior studies have shown that racial disparities exist in intravenous tissue plasminogen activator (tPA) use for acute ischemic stroke. We sought to determine whether race was associated with tPA treatment for stroke in a predominantly black urban population.
METHODS: Systematic chart abstraction was performed on consecutive hospitalized patients with ischemic stroke from all 7 acute care hospitals in the District of Columbia from February 1, 2008, to January 31, 2009.
RESULTS: Of 1044 patients with ischemic stroke, 74% were black, 19% non-Hispanic white, and 5% received intravenous tPA. Blacks were one third less likely than whites to receive intravenous tPA (3% versus 10%, P<0.001). However, blacks were also less likely than whites to present within 3 hours of symptom onset (13% versus 21%, P=0.004) and also less likely to be tPA-eligible (5% versus 13%, P<0.001). Of those who presented within 3 hours, blacks were almost half as likely to be treated with intravenous tPA than whites (27% versus 46%, P=0.023). The treatment rate for tPA-eligible patients was similar for blacks and whites (70% versus 76%, P=0.62).
CONCLUSIONS: In this predominantly black urban population hospitalized for acute ischemic stroke, blacks were significantly less likely to be treated with intravenous tPA due to contraindications to treatment, delayed presentation, and stroke severity. Effective interventions designed to increase treatment in this population need to focus on culturally relevant education programs designed to address barriers specific to this population.
Amie W Hsia; Dorothy F Edwards; Lewis B Morgenstern; Jeffrey J Wing; Nina C Brown; Regina Coles; Sarah Loftin; Andrea Wein; Sara S Koslosky; Sabiha Fatima; Brisa N Sánchez; Ali Fokar; M Chris Gibbons; Nawar Shara; Annapurni Jayam-Trouth; Chelsea S Kidwell
Related Documents :
10953115 - Reassessing the efficacy of the dornier mfl-5000 lithotriptor.
7103715 - Biliary colic and functional gallbladder disease.
17263605 - How do increasing stone surface area and stone configuration affect overall outcome of ...
9187895 - Endopyelotomy with the acucise cutting balloon device. early clinical experience.
15136935 - The probiotic e. coli strain nissle 1917 for the treatment of collagenous colitis: firs...
12771305 - Re-operation is frequently required when parathyroid glands remain after initial parath...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2011-06-30
Journal Detail:
Title:  Stroke; a journal of cerebral circulation     Volume:  42     ISSN:  1524-4628     ISO Abbreviation:  Stroke     Publication Date:  2011 Aug 
Date Detail:
Created Date:  2011-07-26     Completed Date:  2012-08-10     Revised Date:  2013-06-28    
Medline Journal Info:
Nlm Unique ID:  0235266     Medline TA:  Stroke     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2217-21     Citation Subset:  IM    
Washington Hospital Center, Washington, DC 20010, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
African Americans
Aged, 80 and over
Brain Ischemia / drug therapy*
European Continental Ancestry Group
Fibrinolytic Agents / therapeutic use*
Healthcare Disparities*
Middle Aged
Stroke / drug therapy*
Thrombolytic Therapy
Time Factors
Tissue Plasminogen Activator / therapeutic use*
Grant Support
Reg. No./Substance:
0/Fibrinolytic Agents; EC Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Early Ischemic Change on CT Versus Diffusion-Weighted Imaging for Patients With Stroke Receiving Int...
Next Document:  Cost-effectiveness of tissue-type plasminogen activator in the 3- to 4.5-hour time window for acute ...